Table 3

Lifetime risk of all cancers in CDKN2A p.Arg112dup carriers FDRs (n=275) and SDRs (n=321)

FDRsExpected*RR (95% CI)SDRsExpected*RR (95% CI)
Melanoma281.3620.6 (11.6 to 36.7)81.664.8 (2.1 to 10.9)
Pancreas130.621.6 (9.1 to 49.9)30.83.8 (1.1 to 14.9)
Respiratory91.56.0 (2.8 to 13.1)51.82.8 (1.0 to 7.2)
Digestive—upper72.13.3 (1.5 to 7.6)62.62.3 (1.0 to 5.6)
Haematopoietic or lymphatic21.81.1 (0.3 to 4.6)22.20.9 (0.2 to 3.8)
Gynaecological76.71.0 (0.5 to 2.2)88.21.0 (0.5 to 2.0)
Endocrine41.42.9 (1.0 to 8.6)01.70.0
Skin (non-melanoma)42.91.4 (0.5 to 3.9)04.30.0
Breast84.21.9 (0.9 to 4.0)75.11.4 (0.6 to 3.0)
CNS31.42.1 (0.6 to 7.1)01.70.0
Digestive—lower54.31.2 (0.5 to 2.9)25.30.4 (0.1 to 1.5)
Urinary87.31.1 (0.5 to 2.9)128.91.3 (0.7 to 2.5)
Connective tissue10.33.3 (0.3 to 25.3)10.42.5 (0.3 to 20.6)
Unknown primary tumour31.22.5 (0.8 to 8.9)01.40.0
All non-melanoma cancers7435.72.1 (1.6 to 2.7)4644.41.0 (0.8 to 1.4)
  • *In controls, numbers of expected cases are calculated to correspond to equal person years as for carriers.

  • FDR, first degree relative; RR, relative risk; SDR, second degree relative.